Endo’s Par generics unit has launched the first US generic version of Pfizer’s Chantix (varenicline) tablets, entering the market just after the originator recalled the brand over nitrosamine impurities.
Endo’s Par unit has launched the first US generic rival to Pfizer’s (varenicline) tablets, coinciding with current shortages of the product after the originator recalled the brand due to the discovery of nitrosamine impurities.
Confirming that Par has begun shipping varenicline 0.5mg and 1mg tablets – following an early US Food and Drug Administration approval of the product in August (Also see "FDA Looks To Solve Chantix Shortage With Par ANDA Approval" - Generics Bulletin, 17 August, 2021
Apotex has expanded an alliance formed with Formosa in August for its novel clobetasol propionate ophthalmic treatment, adding Mexican rights to its existing deal for the Canadian market.
Fresenius Kabi continued to reap the rewards of its fledgling commercial Biopharma business in the first quarter, as the firm eyes further growth for its tocilizumab biosimilar in the US and Europe in the second half of 2025.
Commissioner Martin Makary’s repeated characterization of foreign facilities as being subject to lower standards than domestic counterparts may have contributed to Rogers’ decision to retire as head of the recently formed Office of Inspections and Investigations.
